Orally administered peptides synergize statin activity

A method of enhancing the activity of a statin, said method comprising:

• coadministering with said statin an effective amount of a peptide or a concatamer of a peptide that:
• ranges in length from about 10 to about 30 amino acids;
• comprises at least one class A amphipathic helix;
• comprises at least one “D” amino acid residue;
• protects a phospholipid against oxidation by an oxidizing agent;
• and is not the D-18A peptide.

A method of mitigating one or more symptoms associated with atherosclerosis in a mammal, said method comprising:

• administering to said mammal an effective amount of a statin;
• and
• an effective amount of a peptide or a concatamer of a peptide that:
• ranges in length from about 10 to about 30 amino acids;
• comprises at least one class A amphipathic helix;
• comprises at least one “D” amino acid residue;
• protects a phospholipid against oxidation by an oxidizing agent;
• and
• is not the D-18A peptide.
• wherein the effective amount of the statin is lower than the effective amount of an statin administered without said peptide.

A pharmaceutical formulation, said formulation comprising:

• a statin;
• and
• a peptide or a concatamer of a peptide that:
• ranges in length from about 10 to about 30 amino acids;
• comprises at least one class A amphipathic helix;
• comprises at least one “D” amino acid residue;
• protects a phospholipid against oxidation by an oxidizing agent;
• and
• is not the D-18A peptide.

A method of reducing or inhibiting one or more symptoms of osteoporosis in a mammal, said method comprising

• administering to said mammal a peptide or a concatamer of a peptide that:
• ranges in length from about 10 to about 30 amino acids;
• comprises at least one class A amphipathic helix;
• comprises at least one “D” amino acid residue;
• protects a phospholipid against oxidation by an oxidizing agent;
• and is not the D-18A peptide;
• wherein said peptide is administered in a concentration sufficient to reduce or eliminate one or more symptoms of osteoporosis.

A method of tracking a peptide in a mammal, said method comprising:

• providing said peptide labeled with N-methyl anthranilyl;
• administering said peptide to said mammal;
• obtaining a biological sample from said mammal;
• and
• detecting or quantifying said N-methyl anthranilyl, wherein said detecting or quantifying provides a measure of the presence or concentration of said peptide in the tissue and/or fluid comprising said sample.